Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

References

• Cancer WHO-IAfRo. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [web page]. World Health Organization; 2012 [cited 2017]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• World Health Organization. GLOBOCAN 2008: cancer incidence and mortality worldwide. World Health Organization, Geneva; 2010.
   Google Scholar
• Coleman MP, Quaresma M, Berrino F, et al. CONCORD working group. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–756.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Breast cancer: prevention and control. World Health Organization, Geneva; 2017.
   Google Scholar
• Taylor D. The reality of economics for oncologists. Breast. 2017 Jun;33:183–190.
   PubMed Web of Science ®Google Scholar
• Burstein H. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20;353(16):1652–1654.
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263–275.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond M, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart M, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–1205.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond E, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N983. J Clin Oncol. 2014;23(31):7811–7819.
   Google Scholar
• Romond EH, J J, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2012;30(31):3792–3799.
   PubMed Web of Science ®Google Scholar
• Advani PP, Ballman K, Dockter TJ, et al. Long term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 2016;34(6):581–587.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Bono P, Kataja V, et al. Fluorouacil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009;27(34):5685–5692.
   PubMed Web of Science ®Google Scholar
• Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27(36):6129–6134.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncol. 2014;53(2):186–194.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Guidelines clinical practice guidelines in oncology- breast cancer version 2. National Comprehensive Cancer Network, Plymouth Meeting; 2017.
   Google Scholar
• Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–30.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Proposal for the inclusion of trastuzumab in the who model list of essential medicines for the treatment of her2-positive breast cancer. World Health Organization, Geneva; 2012.
   Google Scholar
• Chan AL, Leung H, Lu CL, et al. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother. 2009 Feb;43(2):296–303.
   PubMed Web of Science ®Google Scholar
• Petrou P. Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2019 Apr; 19(2):115–125.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health. 2013;16:231–250.
   PubMed Web of Science ®Google Scholar
• Cooper N, Coyle D, Abrams K, et al. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy. 2005 Oct;10(4):245–250.
   PubMedGoogle Scholar
• Fund IM. Implied PPP conversion rate - National currency per international dollar international monetary fund 2018 [cited 2018 Sept 15]. Available from: https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/ADVEC/WEOWORLD
   Google Scholar
• Development OfEC-oa. Exchange rates - total, national currency units/US dollar, 2000 – 2017: organisation for economic co-operation and development 2000 – 2017 [ cited 2018 Sep 14]. Available from: https://data.oecd.org/conversion/exchange-rates.htm
   Google Scholar
• Group TWB. Consumer price index (1960-2017) - international monetary fund, international financial statistics and data files: the world bank group; 2018 [cited 2018 Jul]. Available from: https://data.worldbank.org/indicator/FP.CPI.TOTL
   Google Scholar
• Bank TW. World bank country and lending groups: the world bank; 2018 [cited 2018 Sept 17]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
   Google Scholar
• Neyt M, Albrecht, J, Cocquyt V. An economic evaluation of herceptin in adjuvant setting: the breast cancer international research group 006 trial. Ann Oncol. 2006;17(3):381–390.
   PubMed Web of Science ®Google Scholar
• Dedes K, Szucs TD, Imesch P, et al. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol. 2007;18(9):1493–1499.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007 Aug 1;110(3):489–498.
   PubMed Web of Science ®Google Scholar
• Kurian AW, Thompson R, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007 Feb 20;25(6):634–641.
   PubMed Web of Science ®Google Scholar
• Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2007;25(6):625–633.
   PubMed Web of Science ®Google Scholar
• Norum J, Olsen J, Wist EA, et al. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol. 2007;46(2):153–164.
   PubMed Web of Science ®Google Scholar
• Neyt M, Huybrechts M, Hulstaert F, et al. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy. 2008;87(2):146–159.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008 Jun;109(3):559–566.
   PubMed Web of Science ®Google Scholar
• Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/neu-positive breast cancer: an analysis based on updated results from the HERA trial. Value Health. 2009 Jul-Aug;12(5):641–648. .
   PubMed Web of Science ®Google Scholar
• Van Vlaenderen I, Canon J, Cocquyt V, et al. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clin Belg. 2009 Mar-Apr;64(2):100–112.
   PubMed Web of Science ®Google Scholar
• Macedo A, Monteiro I, Andrade S, et al. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal]. Acta Med Port. 2010 May-Jun;23(3):475–482.
   PubMed Web of Science ®Google Scholar
• Hall PS, Hulme C, McCabe C, et al. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. Pharmacoeconomics. 2011 May;29(5):415–432.
   PubMed Web of Science ®Google Scholar
• Hedden L, O’Reilly RS, Lohrisch C, et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist. 2012;17(2):164–171.
   PubMed Web of Science ®Google Scholar
• Lang HC, Chen H, Chiou TJ, et al. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. J Med Econ. 2016 Oct;19(10):923–927.
   PubMed Web of Science ®Google Scholar
• Leung W, Kvizhinadze G, Nair N, et al. Adjuvant Trastuzumab in HER2-positive early breast cancer by age and hormone receptor status: a cost-utility analysis. PLoS Med. 2016 Aug 9;;13(8):e1002067.
   PubMed Web of Science ®Google Scholar
• Seferina SC, Ramaekers B, de Boer M, et al. Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands breast cancer consortium. Oncotarget. 2017;8(45):79223–79233.
   PubMedGoogle Scholar
• Chen W, Jiang Z, Shao Z, et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009 Nov-Dec;12(Suppl 3):S82–4.
   PubMed Web of Science ®Google Scholar
• Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013 Jul-Sep;33(3):411–417.
   PubMed Web of Science ®Google Scholar
• Aboutorabi AHM, Ghaderi H, Salehi M, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. Glob J Health Sci. 2014 Aug 14;;7(1):98–106.
   PubMedGoogle Scholar
• Pichon-Riviere A, Garay O, Augustovski F, et al. Implications of global pricing policies on access to innovative drugs: the case of trastuzumab in seven Latin American countries. Int J Technol Assess Health Care. 2015 Jan;31(1–2):2–11.
   PubMed Web of Science ®Google Scholar
• Ansaripour A, Uyl-de Groot CA, Redekop WK. Adjuvant trastuzumab therapy for early HER2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. Pharmacoeconomics. 2018;36(1):91–103.
   PubMed Web of Science ®Google Scholar
• Kongsakon R, Lochid-Amnuay S, Kapol N, et al. From research to policy implementation: trastuzumab in early-stage breast cancer treatment in Thailand. Value Health Reg Issues. 2018;18:47–53.
   PubMedGoogle Scholar
• World Health Organization. Essential medicines selection: trastuzumab.  World Health Organization, Geneva. (cited 2020 Aug 24). 2013.
   Google Scholar
• World Health Organization. Out-of-pocket expenditure as a percentage of total expenditure on health 2014 [cited 2020 Aug 24]. Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/out-of-pocket-expenditure-as-a-percentage-of-total-expenditure-on-health
   Google Scholar
• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015 March 14;385(9972):977–1010.
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Puglisi F, Molino AM, et al. Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients. Future Oncol. 2015;11(10):1493–1500.
   PubMed Web of Science ®Google Scholar
• Barbier L, Declerck P, Simoens S, et al. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer. 2019;121(3):199–210.
   PubMed Web of Science ®Google Scholar
• Deloitte. Winning with biosimilars: opportunities in global markets 2015 [ cited 2020 August 24]. Available from: https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-biosimilars-whitepaper-final.pdf
   Google Scholar
• Debiasi M, Polanczyk C, Ziegelmann P, et al. Efficacy of anti-HER2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced HER2-positive breast cancer patients: a network meta-analysis. Front Oncol. 2018;8:156.
   PubMed Web of Science ®Google Scholar